Michal Becker- Cohen
Jerusalem, Please Select..., 9103102, Israel
Location status: Recruiting
Location contact
Ari Zimran, M.D.
CONTACT
Ari Zimran, Prof.
PRINCIPAL_INVESTIGATOR
Michal Becker- Cohen, M.Sc.
CONTACT
NCT Number: NCT05253560
Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.
A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.
Interested in participating?
Request Info40 year–75 year
All sexes
Observational
Jerusalem, Please Select..., 9103102, Israel
Location status: Recruiting
Ari Zimran, M.D.
CONTACT
Ari Zimran, Prof.
PRINCIPAL_INVESTIGATOR
Michal Becker- Cohen, M.Sc.
CONTACT
The carriers, the healthy people and the Gaucher patients will undergo a number of non-invasive tests, which test the pre-Parkinson signs.
The tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
Time frame: 8 Years
Carriers of a variant in the GBA1 gene (GBA carriers) are at the highest risk of developing Parkinson disease (PD). A screening study for prodromal PD features in a cohort of obligatory GBA carriers between 40-75 years was initiated to identify candidates for a PD prevention trial. We added healthy controls and GD patients in order to determine the incidence of prodromal PD and for analyzing the differences between the two groups helping to build a model for identifying at risk PD at the prodromal stage.
Participants preform 15 pre-defined non-invasive tests for prodromal PD and assessment of risk factors. Risk factors for PD included age, sex, type of GBA1 variant, coffee and tea caffeine consumption, smoking habits, exposure to solvents and pesticides, and family history of PD (1st and/or 2nd degree relatives with PD).
Time frame: 8 years
Transcranial sonography (TCS) is a useful noninvasive diagnostic tool to detect hyperechogenicity (SN+) of the substantia nigra area in the brain. The hyperechogenicity happens due to increased amounts of iron, reflecting a functional impairment.
Time frame: 8 years
Color discrimination was analyzed using The Farnsworth-Munsell 100 hue test. The test includes four boxes with a fixed number of color shade caps with slight shade differences needed to be ordered correctly. The result of each box was entered into a computerized system and automated the total error score (TES)
Time frame: 8 years
The shorter version of the UPSIT smell test (The University of Pennsylvania Smell Identification Test) was used to evaluate hyposmia using twelve cards, each with a different smell.
Time frame: 8 years
defined as a fall of at least 20 mmHg systolic or at least ten mmHg diastolic blood pressure by 3 min of active standing or head-up tilt
Time frame: 8 years
evaluate the cognitive and mental aspects associated with PD. A Montreal Cognitive Assessment (MoCA) score of 26 and above was considered normal
Time frame: 8 years
The NeuroTrax computerized battery (www.neurotrax.com) includes seven sections: memory, executive function, attention, information processing speed, visual-spatial, verbal function, and motor skills
Time frame: 8 years
self-administered questioner including 21 questions used to screen, diagnose, and measure the severity of depression.
Time frame: 8 years
evaluates executive dysfunction
Time frame: 8 years
Idiopathic rapid eye movement sleep behavior disorder is an important risk factor in the diagnosis of PD. The REM questionnaire was completed by the participant.
Time frame: 8 years
assessing daytime sleepiness includes an eight-question questionnaire scoring between 0 and 24; the higher the score, the higher the chances of dosing off
Time frame: 8 years
Perdue pegboard measures the movement of fingers, hands, and arms in 4 different tasks, testing motor abilities and coordination by placing as many pegs and discs on a board in three 30 seconds trials for each subset and three 60 second trials for the assembly subset
Time frame: 8 years
measures gross motor function. A score above 6, not including postural and action tremor, was considered abnormal
Time frame: 8 years
The Timed Up and Go (iTUG) (EncephaLogTM) is a platform that utilizes smartphones' internal motion sensors for conducting motor evaluation including general walking score, step to step persistency, hand sway and rotation time.
Time frame: 8 years
Spontaneous bowel movement frequency was used to define constipation. Urinary and erectile dysfunction were assessed according to the MDS criteria
Contact information is provided by the study sponsor or research team.
Ari Zimran, MD
CONTACT
Michal Becker- Cohen, M.Sc.
CONTACT
Shaare Zedek Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05487599
Brain Diseases, Brain Diseases, Metabolic
Los Angeles, California, United States
View Trial DetailsNCT05324943
Brain Diseases, Brain Diseases, Metabolic
Los Angeles, California, United States
View Trial DetailsNCT06545136
Brain Diseases, Brain Diseases, Metabolic
Fairfax, Virginia, United States
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial Details